Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

Varicella-Zoster Virus IE63, a Major Viral Latency Protein, Is Required To Inhibit the Alpha Interferon-Induced Antiviral Response

Aruna P. N. Ambagala, Jeffrey I. Cohen
Aruna P. N. Ambagala
Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey I. Cohen
Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jcohen@niaid.nih.gov
DOI: 10.1128/JVI.00325-07
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    (A) Immunofluorescent foci of ROka and ROka63D in MeWo, U2OS, and Saos-2 cells. Cells infected with ROka or ROka63D were stained with anti-VZV gE mouse monoclonal antibody, followed by fluorescein isothiocyanate-labeled goat anti-mouse immunoglobulin G antibody. (B) Growth of ROka and ROka63D in U2OS and Saos-2 cells. U2OS and Saos-2 cells were inoculated with VZV-infected MeWo cells. Cells were harvested on days 1 to 6 after infection, and virus titers were determined by plating on MeWo cells. The virus titer on day zero represents the titer of the input inoculum.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Effect of IFN-α (A) and IFN-γ (B) on plaque formation by ROka and VZV deletion mutants in MeWo cells. MeWo cells were untreated or pretreated with IFN-α (1,000 IU/ml) or IFN-γ (1,000 IU/ml) for 18 h and infected with ROka, ROka63D, ROka61D, or ROka67D. Plaques were counted 6 days (for ROka) or 10 days (for deletion mutants) after infection. The efficacy of IFN treatment was measured by the ratio of the number of plaques in IFN-untreated wells to the number of plaques in IFN-treated wells. The results from three experiments were analyzed by one-way analysis of variance, and the Welch modified t test was used to calculate P values. The error bars represent standard deviations.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    VZV IE63 expressed in trans overcomes the effect of IFN-α in ROka63D-infected cells. MeWo cells were infected with control adenovirus (Adblank) or adenovirus expressing VZV IE63 protein (Ad63) for 5 h and treated with IFN-α (1,000 IU/ml) for 18 h. The cells were then infected with serial dilutions of ROka63D, and 10 days after infection, the monolayers were stained with crystal violet.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Effects of IFN-α on replication of ROka and ROka63D in U2OS and MeWo cells. Monolayers of U2OS and MeWo cells were untreated or pretreated with IFN-α (1,000 IU/ml) for 18 h. The cells were then infected with ROka or ROka63D. Four days after infection, the cells were harvested and the titer of each virus was determined on MeWo cells. The efficacy of IFN-α treatment was measured as described in the legend to Fig. 3. The error bars represent standard deviations.

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Immunofluorescence staining with antibodies to VZV gE and IE62 of VZV-infected, IFN-α-untreated, or IFN-α-pretreated MeWo cells. MeWo cells treated with human IFN-α (1,000 IU/ml) or untreated were infected with ROka, ROka63D, ROka61D, or ROka67D. On the indicated days after infection, the cells were fixed and stained with antibodies to VZV gE (A) or VZV IE62 (B) or with DAPI (A, bottom). The data are representative of one of two independent experiments.

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Immunoblots of VZV IE, putative early, and late proteins in MeWo cells untreated (−) or pretreated (+) with IFN-α. (A) MeWo cells untreated or pretreated with IFN-α (1,000 IU/ml) were infected with ROka, ROka63D, or ROka61D. Cell lysates were prepared 2 days after infection and immunoblotted with antibodies to VZV IE62, TK, gE, IE63, ORF61 protein, or cellular β-actin. (B) The VZV protein bands were quantified using a densitometer and normalized to the corresponding β-actin band. The reduction (n-fold) in protein expression due to IFN-α treatment was determined as the ratio of normalized densitometry values from IFN-α-untreated cells to that from IFN-α-treated cells. The data are representative of one of two independent experiments.

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Northern blots of VZV IE, putative early, and late transcripts in MeWo cells in the presence (+) or absence (−) of IFN-α. (A) MeWo cells untreated or pretreated with human IFN-α (1,000 IU/ml) were infected with ROka, ROka63D, or ROka61D. Total RNA was isolated 2 days after infection, and Northern blots were performed using radiolabeled DNA probes specific for VZV IE62, TK, gE, and cellular β-actin. (B) Bands were quantified using a densitometer, and each band was normalized to the area of the corresponding β-actin band. Reduction (n-fold) in mRNA expression due to IFN-α treatment was calculated as the ratio of densitometry values from IFN-α-untreated cells to that from IFN-α-treated cells. The data are representative of one of two independent experiments.

  • FIG. 8.
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    Immunoblot of eIF-2α phosphorylation in ROka, ROka63D, or ROka61D-infected MeWo cells. Mewo cells were infected with ROka, ROka63D, or ROka61D; cell lysates were prepared 2 days after infection; and immunoblots were performed using antibodies to phosphorylated or total eIF-2α, VZV ORF4, or gE. Lysates from thapsigargin (Tgn)-treated MeWo cells were used as a positive control, and lysates from uninfected or dimethyl sulfoxide (DMSO)-treated cells were negative controls for eIF-2α-P. The data are representative of one of three independent experiments.

  • FIG. 9.
    • Open in new tab
    • Download powerpoint
    FIG. 9.

    Immunoblot of phosphorylated and total eIF-2α in Cos cells expressing VZV ORF63. Cos cells were transfected with the indicated plasmids, and 2 days later, cell lysates were prepared and immunoblotted with antibodies to phosphorylated or total eIF-2α. The numbers below the bands indicate signal intensities relative to that of untransfected cells. The data are representative of one of three independent experiments.

PreviousNext
Back to top
Download PDF
Citation Tools
Varicella-Zoster Virus IE63, a Major Viral Latency Protein, Is Required To Inhibit the Alpha Interferon-Induced Antiviral Response
Aruna P. N. Ambagala, Jeffrey I. Cohen
Journal of Virology Jul 2007, 81 (15) 7844-7851; DOI: 10.1128/JVI.00325-07

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Varicella-Zoster Virus IE63, a Major Viral Latency Protein, Is Required To Inhibit the Alpha Interferon-Induced Antiviral Response
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Varicella-Zoster Virus IE63, a Major Viral Latency Protein, Is Required To Inhibit the Alpha Interferon-Induced Antiviral Response
Aruna P. N. Ambagala, Jeffrey I. Cohen
Journal of Virology Jul 2007, 81 (15) 7844-7851; DOI: 10.1128/JVI.00325-07
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Herpesvirus 3, Human
Immediate-Early Proteins
Interferon-alpha
Viral Envelope Proteins
Viral Proteins

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514